Marinomed Biotech AG (MARI.VI)
EUR 12.0
(-2.83%)
EUR 12.0
(-2.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.62 Million EUR | -81.21% |
| 2022 | -3.21 Million EUR | 10.16% |
| 2021 | -3.57 Million EUR | 26.47% |
| 2020 | -4.86 Million EUR | 17.32% |
| 2019 | -6.21 Million EUR | -83.97% |
| 2018 | -10.36 Million EUR | -122.4% |
| 2017 | -1.22 Million EUR | -7.01% |
| 2016 | -1.34 Million EUR | -29.07% |
| 2015 | -1.06 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.71 Million EUR | -237.91% |
| 2023 FY | - EUR | -81.21% |
| 2023 Q1 | -1.22 Million EUR | -1556.79% |
| 2023 Q2 | -1.53 Million EUR | -25.79% |
| 2023 Q3 | -1.32 Million EUR | 13.95% |
| 2023 Q4 | -563.4 Thousand EUR | 57.46% |
| 2022 Q1 | -1.07 Million EUR | -190.74% |
| 2022 FY | - EUR | 10.16% |
| 2022 Q4 | 84 Thousand EUR | 107.36% |
| 2022 Q3 | -1.14 Million EUR | -5.23% |
| 2022 Q2 | -1.08 Million EUR | -1.04% |
| 2021 Q1 | -1.61 Million EUR | -81.87% |
| 2021 Q3 | -1.39 Million EUR | 19.9% |
| 2021 Q4 | 1.18 Million EUR | 184.51% |
| 2021 FY | - EUR | 26.47% |
| 2021 Q2 | -1.74 Million EUR | -8.26% |
| 2020 Q1 | -1.31 Million EUR | -11.35% |
| 2020 Q3 | -1.28 Million EUR | 6.59% |
| 2020 Q4 | -887 Thousand EUR | 31.04% |
| 2020 FY | - EUR | 17.32% |
| 2020 Q2 | -1.37 Million EUR | -4.76% |
| 2019 Q2 | -1.34 Million EUR | 50.64% |
| 2019 Q1 | -2.71 Million EUR | -873.52% |
| 2019 Q4 | -1.18 Million EUR | -2.94% |
| 2019 FY | - EUR | -83.97% |
| 2019 Q3 | -1.14 Million EUR | 14.44% |
| 2018 Q1 | -1.03 Million EUR | -853.4% |
| 2018 FY | - EUR | -122.4% |
| 2018 Q4 | -278.94 Thousand EUR | 77.58% |
| 2018 Q3 | -1.24 Million EUR | -213.37% |
| 2018 Q2 | -397.03 Thousand EUR | 61.54% |
| 2017 Q4 | 137.01 Thousand EUR | 0.0% |
| 2017 FY | - EUR | -7.01% |
| 2016 FY | - EUR | -29.07% |
| 2015 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|